title: Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates.
abstract: A critical need for combating the effects of organophosphate (OP) anticholinesterases, such as nerve agents, is the current lack of an effective oxime reactivator which can penetrate the blood-brain barrier (BBB), and therefore reactivate inhibited acetylcholinesterase (AChE) in the brain. Our laboratories have synthesized and have initiated testing of novel phenoxyalkyl pyridinium oximes (patent pending) that are more lipophilic than currently approved oximes. This is a preliminary report on these novel oximes which have been tested in vitro in rat brain homogenates with highly relevant surrogates for sarin (phthalimidyl isopropyl methylphosphonate; PIMP) and VX (nitrophenyl ethyl methylphosphonate; NEMP). The oximes demonstrated a range of 14-76% reactivation of rat brain AChE in vitro. An in vivo testing paradigm was developed in which the novel oxime was administered at the time of maximal brain AChE inhibition (about 80%) (1h) elicited by nitrophenyl isopropyl methylphosphonate (NIMP; sarin surrogate). This paradigm, with delayed administration of oxime to a time when brain AChE was starting to recover, was designed to minimize reactivation/reinhibition of peripheral AChE during the reactivation period which would decrease the availability of the surrogate for entry into the brain; this paradigm will allow proof of concept of BBB penetrability. The initial studies of these oximes in vivo with the sarin surrogate NIMP have indicated reactivation of up to about 25% at 30 min after oxime administration and substantial attenuation of seizure behavior from some of the oximes. Therefore these novel oximes have considerable potential as brain-protecting therapeutics for anticholinesterases.
authors.affiliation: Center for Environmental Health Sciences, College of Veterinary Medicine, PO Box 6100, Mississippi State University, Mississippi State, MS 39762-6100, USA. chambers@cvm.msstate.edu
authors.forename: Janice E
authors.initials: JE
authors.lastname: Chambers
authors.forename: Howard W
authors.initials: HW
authors.lastname: Chambers
authors.forename: Edward C
authors.initials: EC
authors.lastname: Meek
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Pringle
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism*; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002619:Chemical Warfare Agents / Q000633:toxicity; D002800:Cholinesterase Inhibitors / Q000633:toxicity; D002801:Cholinesterase Reactivators / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D058851:GPI-Linked Proteins / Q000378:metabolism; D008297:Male; D010755:Organophosphates / Q000633:toxicity; D009946:Organothiophosphorus Compounds / Q000633:toxicity; D010091:Oximes / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012524:Sarin / Q000031:analogs & derivatives / Q000633:toxicity; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000110:Acetylcholinesterase; D002619:Chemical Warfare Agents; D002800:Cholinesterase Inhibitors; D002801:Cholinesterase Reactivators; D058851:GPI-Linked Proteins; D010755:Organophosphates; D009946:Organothiophosphorus Compounds; D010091:Oximes; D012524:Sarin; C009680:VX-agent; C548246:Ache protein, rat